Evidence map›Paper›PMID 23982993›Full record

ReviewBiotechnology and bioengineering2014

Expanding the scope of site-specific recombinases for genetic and metabolic engineering.

Thomas Gaj, Shannon J Sirk, Carlos F Barbas

Open access · greenAbstract readReview
In one paragraph

Review in Biotechnology and bioengineering, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 89 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Dynamics in Cre-loxP site-specific recombination.Current opinion in structural biology · 2024
    Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Thomas GajThe Skaggs Institute for Chemical Biology and the Departments of Chemistry and Cell and Molecular Biology, The Scripps Research Institute, La Jolla, California, 92037.
Shannon J Sirk
Carlos F Barbas
Scripps Research Institute · US

Funding

Chemically Programmed ImmunityDP1CA174426 · NCI · SCRIPPS RESEARCH INSTITUTE, THE · PI DAWSON, PHILIP E · 2012 to 2014
$2.3M
Predoctoral Training Program in Molecular EvolutionT32GM080209 · NIGMS · SCRIPPS RESEARCH INSTITUTE, THE · PI FINN, M.G. · 2009 to 2011
$461k
NCI NIH HHS DP1 CA174426NCI NIH HHS DP1CA174426NIGMS NIH HHS T32 GM080209NIGMS NIH HHS T32GM080209
6 · The paper itself

Abstract

Site-specific recombinases are tremendously valuable tools for basic research and genetic engineering. By promoting high-fidelity DNA modifications, site-specific recombination systems have empowered researchers with unprecedented control over diverse biological functions, enabling countless insights into cellular structure and function. The rigid target specificities of many sites-specific recombinases, however, have limited their adoption in fields that require highly flexible recognition abilities. As a result, intense effort has been directed toward altering the properties of site-specific recombination systems by protein engineering. Here, we review key developments in the rational design and directed molecular evolution of site-specific recombinases, highlighting the numerous applications of these enzymes across diverse fields of study.

Indexed as

Genetic EngineeringMetabolic EngineeringRecombinasesAmino Acid SequenceAnimalsBase SequenceHumansMiceModels, MolecularMolecular Sequence DataRecombinasesgenome engineeringprotein engineeringrecombinase

Identifiers

PMID23982993
PMCPMC4097888
OpenAlexW2138799439

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.